ArticleTheranostics2019
Integration of metabolomics and expression of enolase-phosphatase 1 links to hepatocellular carcinoma progression.
Article in Theranostics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Targeting one-carbon metabolic vulnerabilities of metastasis with therapeutic potential.bioRxiv : the preprint server for biology · 2026Article
- Construction of molecular subtypes and prognostic model for breast cancer based on sulfur metabolism-related genes.Translational cancer research · 2025Article
- Comprehensive pan-cancer analysis of ENOPH1 in human tumors.Discover oncology · 2025Article
- A gene pathway enrichment method based on improved TF-IDF algorithm.Biochemistry and biophysics reports · 2023Article
- Amino acid metabolism genes associated with immunotherapy responses and clinical prognosis of colorectal cancer.Frontiers in molecular biosciences · 2022Article
- Circulating Metabolic Markers Related to the Diagnosis of Hepatocellular Carcinoma.Journal of oncology · 2022Review
- Malic enzyme 2 promotes the progression of hepatocellular carcinoma via increasing triglyceride production.Cancer medicine · 2021Article
- Construction and validation of a metabolic risk model predicting prognosis of colon cancer.Scientific reports · 2021Article
- CMTM6 drives cisplatin resistance by regulating Wnt signaling through the ENO-1/AKT/GSK3β axis.JCI insight · 2021Article
- Hepatomas are exquisitely sensitive to pharmacologic ascorbate (P-AscHTheranostics · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Reprogramming of cellular metabolism is one of the hallmarks for cancer, in which tumor cells rewire their metabolic fluxes to generate sufficient energy and biosynthetic intermediates. Therefore, elucidating the correlation between cellular metabolism and hepatocellular carcinoma (HCC) progression may provide insights into novel approaches to cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.